Yahoo
MCE - Delayed Quote EUR

Faes Farma, S.A. (FAE.MC)

4.8200 0.0000 (0.00%)
As of 10:05:24 AM GMT+1. Market Open.
Chart Range Bar
Loading chart for FAE.MC
  • Previous Close 4.8200
  • Open 4.8350
  • Bid 4.8050 x --
  • Ask 4.8350 x --
  • Day's Range 4.8000 - 4.8350
  • 52 Week Range 4.3150 - 5.4400
  • Volume 11,262
  • Avg. Volume 158,535
  • Market Cap (intraday) 1.501B
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) 17.85
  • EPS (TTM) 0.2700
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield 0.13 (2.66%)
  • Ex-Dividend Date Jul 2, 2026
  • 1y Target Est 5.43

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. The company also provides animal nutrition and health products. It offers products for various therapeutic areas. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

faesfarma.com

2,677

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is IBEX 35 (^IBEX) .

YTD Return

FAE.MC
3.10%
IBEX 35 (^IBEX)
8.65%

1-Year Return

FAE.MC
11.03%
IBEX 35 (^IBEX)
17.61%

3-Year Return

FAE.MC
80.85%
IBEX 35 (^IBEX)
103.62%

5-Year Return

FAE.MC
72.72%
IBEX 35 (^IBEX)
107.08%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 172.08M
Earnings 17.25M
Profit Margin 10.02%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%

Analyst Insights

View More

Analyst Price Targets

4.82
5.43 Average
4.8200 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.89%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    736.53M

  • Net Income Avi to Common (ttm)

    80.2M

  • Diluted EPS (ttm)

    0.2700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    136.78M

  • Total Debt/Equity (mrq)

    57.95%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: